Vicore Pharma (VICO) investor relations material

Strategic vision and financial position

• Aims to transform patient outcomes by targeting the AT2 receptor to halt and reverse disease pathology.

• Operates from Stockholm, Cambridge, and Copenhagen, with dual listings on Nasdaq Stockholm and Nasdaq US.

• Market capitalization stands at $320 million, with $93 million in financial reserves as of mid-2026.

• Supported by leading specialist investors in the US and Europe.

Lead program and clinical pipeline

• Buloxibutid, an oral AT2 receptor agonist, is the lead candidate for idiopathic pulmonary fibrosis (IPF).

• Received Orphan Drug and Fast Track designations from the FDA.

• Currently in a global Phase 2b trial (ASPIRE) for IPF, with topline data expected mid-2027.

• Global rights held except for Japan, where partnered with Nippon Shinyaku.

Market opportunity and unmet need

• IPF is a progressive, fatal disease with high unmet need and limited effective therapies.

• Global IPF market projected to grow from $4.2B in 2024 to over $10B by 2030-2033.

• Existing therapies offer only modest slowing of disease progression and have significant side effects.

• Only about 25% of US patients initiate treatment, with high discontinuation rates.